Kengreal
Kengreal Uses, Dosage, Side Effects, Food Interaction and all others data.
Kengreal is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Kengreal provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Kengreal was approved by the FDA in June 2015 for intravenous application.
| Trade Name | Kengreal |
| Availability | Prescription only |
| Generic | Cangrelor |
| Cangrelor Other Names | Cangrelor |
| Related Drugs | clopidogrel, Plavix, Integrilin, Angiomax, eptifibatide, bivalirudin |
| Type | Intravenous |
| Formula | C17H25Cl2F3N5O12P3S2 |
| Weight | Average: 776.35 Monoisotopic: 774.9483145 |
| Protein binding | about 97-98%. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Kengreal is a P2Y12 platelet receptor antagonist used during percutaneous coronary intervention to reduce the risk for periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST).
For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Kengreal is also used to associated treatment for these conditions: Post procedural myocardial infarction, Stent Thrombosis, Repeat coronary revascularization
How Kengreal works
Kengreal is a selective, reversible, P2Y12 platelet receptor antagonist which inhibits ADP platelet aggregation. ADP is typically released by damaged blood vessels, red blood cells, and/or platelets due to agonists stimulating platelet activity. ADP binds to P2Y12 to stimulate and complete platelet aggregation by inhibiting adenylyl cyclase by a Gi protein, thus potentiating dense granule secretion and increasing coagulation activity. Kengreal acts on the same target as oral irreversible inhibitors clopidogrel and ticlopidine and has a similar mechanism of action, but is reversible and provides a fast onset and offset of action.
Food Interaction
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Kengreal Disease Interaction
Volume of Distribution
In a study in healthy volunteers administration at a dose of 30 mcg/kg bolus plus 4 mcg/kg/min showed a volume of distribution of 3.9 L.
Half Life
The average elimination half-life of cangrelor is about 3-6 minutes.
Clearance
The mean clearance is about 43.2 L/h.
Elimination Route
Following IV administration of [3H] cangrelor, 58% of radioactivity was recovered in urine. The remaining 35% of radioactivity was in feces, presumably following biliary excretion.
Innovators Monograph
You find simplified version here Kengreal
